In contrast, there might be fewer or no effects of PMS2 germline pathogenic variants because the cancer itself did not exhibit MSI-H or MMR deficiency in CGP analysis and MMR immunohistochemistry. The gene discussed is PMS2; the disease is mismatch repair cancer syndrome 1.